Addressing Neurodegeneration by Targeting the Underlying Biology
Priavoid is developing a novel class of orally available all-d-peptide therapeutics that inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.
About us
Our Mission: Detangling neurodegeneration
We are pioneering a distinctive mode of action that allows us to disassemble neurotoxic protein aggregates in a way that has not been possible before. Based on our differentiated technology and decades of expertise in protein aggregation biology, our dedicated team strives to unlock a new way to address neurodegenerative disorders.
Our Pipeline
Advancing disease-modifying treatments
Priavoid’s lead pipeline program, PRI-002, is currently in Phase 2 clinical development for Alzheimer’s disease. The company is also advancing PRI-101 for synucleinopathies, including Parkinson’s disease and multiple system atrophy, and PRI-200, a tau-targeting program in preclinical development. In addition, Priavoid is progressing a focused set of platform-derived programs targeting neurotoxic protein aggregation in additional indications such as amyotrophic lateral sclerosis.
Our Technology
A differentiated detangler platform
Through its proprietary development platform, Priavoid is advancing a focused pipeline of all-D-peptide compounds designed to detangle a broad range of neurotoxic protein aggregates. Our candidates are non-immunogenic and reach their targets in the brain and inside the affected cells, enabling them to inhibit and reverse disease-specific protein aggregation.
Partnering opportunities
Joining forces to advance a new therapeutic approach to tackle neurodegenerative diseases
Our goal is to translate our technology into treatments that address the underlying biology of neurodegeneration and deliver meaningful clinical benefit for patients. We welcome the exchange with potential new partners and collaborators who share our ambition to unlock the full clinical potential of our detangler approach.